Prior animal studies revealed the repeated TLR-9 model requires IFN-γ for full manifestation of MAS or lung findings; IFN-γ blockade also ameliorates symptoms in IL-6TG mouse too. Here, TLR9 is linked to macrophage activation syndrome.